Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

Condition(s) targeted: Pseudomonas Infection

Intervention: Ciprofloxacin (Cipro, BAYQ3939) (Drug)

Phase: Phase 1

Status: Recruiting

Sponsored by: Bayer

Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer

Overall contact:
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com

Ciprofloxacin PulmoSphere Inhalation Powder appears to be an effective and adequate antibiotic treatment for cystic fibrosis patients with P. aeruginosa colonisation.

This planned study is the first study on the use of this new Ciprofloxacin PulmoSphere Inhalation Powder in the pediatric population of 6 to 12 years of age.

Official title: A Study to Evaluate the Safety and Pharmacokinetics of Ciprofloxacin in Adults and Children Aged 6 - 12 Years With Cystic Fibrosis Following Inhalation of Ciprofloxacin Dry Powder

Study design: Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety Study

Primary outcome: To investigate the safety and tolerability of inhaled ciprofloxacin given as single inhalation dose to pediatric CF patients, aged 6 - 12 years

Secondary outcome: To investigate the pharmacokinetics of ciprofloxacin in plasma and sputum after inhalation administration

Minimum age: 6 Years. Maximum age: 12 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female patients with cystic fibrosis confirmed by genetic testing and / or by

sweat test

- Colonization with P. aeruginosa confirmed in sputum in the past 12 months

- Cohort 1: greater than or equal to 18 years of age.

- Cohort 2: 6 - 12 years of age (inclusive)

- Normal Body Mass Index: BMI between 14. 5 and 30 kg/m2, but in no case lower than

the 30th percentile for age. Because CFpatients are typically smaller than non-CF-patients, the normal body mass index will be based on standard CF foundation normal values for weight and sex.

- Patients who are able to understand and follow instructions and who are able to

participate in the study for the entire period.

- Patients and legal representatives must have given their written informed consent to

participate in the study after receiving adequate previous information and prior to any study specific procedures

Exclusion Criteria:

- Patients with FEV1 < 35% of predicted. 1, 2. FEV1 (forced expiratory volume) is a

measure of lung function. This exclusion will prohibit enrollment of patients with severely impaired lung function.

- Patients with Burkholderia cepacia colonization of their respiratory tract

- Patients with acute bronchopulmonary aspergillosis (ABPA)

- Patients on a lung transplant list

- Patients with acute pulmonary exacerbations

- Patients with severe liver cirrhosis

- Massive hemoptysis in the preceding 4 weeks

- A history of relevant diseases of vital organs, of the central nervous system, or

other organs not related to the underlying disease

- Patients with a history of severe allergies, non-allergic drug reactions, or multiple

drug allergies

- Patients with hypersensitivity to the investigational drug or to other quinolones

and/ or to inactive constituents

- Patients with known intolerance to hypertonic saline or bronchodilators

- Concomitant inhalation therapy with antibiotics and / or concomitant systemic therapy

with fluoroquinolones

- Women who are pregnant

Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com

Boston, Massachusetts 02115, United States; Recruiting

Syracuse, New York 13210, United States; Not yet recruiting

Click here and search for drug information provided by the FDA

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product

Click here to find results for studies related to marketed products

Starting date: July 2009
Ending date: February 2010
Last updated: October 9, 2009